X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Rebecca Davison

Rebecca Davison Becca is a Director in the Policy and Research Department at PhRMA focusing on Medicaid, the Affordable Care Act and 340B. Prior to getting her Masters of Public Policy at the McCourt School of Public Policy at Georgetown University, she worked for the American Academy of Pediatrics and for Senator Christopher J. Dodd of Connecticut. In her spare time, Becca enjoys traveling and cooking and is a die-hard New York Yankees fan.

Recent Posts

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

340B Spotlight: Program continues to grow with no end in sight

By Rebecca Davison  |    October 4, 2016
How much is the 340B program growing? Earlier this year, Drug Channels published new 340B purchase data from Apexus, the 340B program’s Prime Vendor.  Apexus’s data show $12 billion of drug sales...   Read More

Making drug formulary search tools better for patients

By Rebecca Davison  |    September 7, 2016
There is a real need for patients to have information about out-of-pocket costs and clinical tools being used when it comes to their coverage. A new prescription drug search tool that includes...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in...   Read More

Many consumers still face confusion around health insurance coverage

By Rebecca Davison  |    May 25, 2016
Consumers need to be engaged and empowered when making decisions about their health coverage. Two recent studies suggest more can be done to help consumers sort through their health insurance...   Read More

A state-by-state look at coverage and access hurdles in 2016 exchange plans

By Rebecca Davison  |    May 6, 2016
We frequently talk about access barriers patients with health insurance exchange plans face, including two recent studies from Avalere Health and Harvard University Center for Health Law and...   Read More

340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements

By Rebecca Davison  |    April 28, 2016
Late last year, we highlighted a study published in in the New England Journal of Medicine that found many nonprofit hospitals were not complying with the charity care requirements laid out in the   Read More

Impact of deductibles in health plans

By Rebecca Davison  |    November 18, 2015
We’ve seen reports on the use of high deductibles that include prescription drugs in health insurance exchange plans and the burden they put on patients. A recent IMS Health report, Emergence and...   Read More

3 Tiers, 4 Tiers, 5 Tiers and More – A look at tiering in health insurance exchange plans

By Rebecca Davison  |    October 22, 2015
One size fits all rarely works for clothing, and it turns out, it doesn’t work for prescription drug coverage either. Health insurance plans cover prescription drugs through formularies, which...   Read More

340B Spotlight: Rapid growth of contract pharmacies

By Rebecca Davison  |    October 8, 2015
Last week we covered the basics around contract pharmacies in the 340B program. Today we’re taking a closer look at contract pharmacies as a relatively new source of growth in the program. ...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates